L. Mauriac is a scholar working on Oncology, Cancer Research and Genetics.
According to data from OpenAlex, L. Mauriac has authored 171 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Oncology, 83 papers in Cancer Research and 64 papers in Genetics. Recurrent topics in L. Mauriac's work include Breast Cancer Treatment Studies (77 papers), Cancer Treatment and Pharmacology (59 papers) and Estrogen and related hormone effects (58 papers). L. Mauriac is often cited by papers focused on Breast Cancer Treatment Studies (77 papers), Cancer Treatment and Pharmacology (59 papers) and Estrogen and related hormone effects (58 papers). L. Mauriac collaborates with scholars based in France, Belgium and United States. L. Mauriac's co-authors include J.F.R. Robertson, M. Durand, Ignace Vergote, Beat Thürlimann, Matthew J. Ellis, Gaëtan MacGrogan, Alan Webster, A. Avril, Stephen E. Jones and Jacques Bonneterre and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
In The Last Decade
L. Mauriac
164 papers
receiving
11.0k citations
Hit Papers
What are hit papers?
Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
20051.2k citationsMichel Marty, Francesco Cognetti et al.IRIS UNIMORE (University of Modena and Reggio Emilia)profile →
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
2002855 citationsJoyce O’Shaughnessy, David Miles et al.Journal of Clinical Oncologyprofile →
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
2001790 citationsMatthew J. Ellis, Andrew Coop et al.Journal of Clinical Oncologyprofile →
Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98
2007693 citationsAlan S. Coates, Aparna Keshaviah et al.Journal of Clinical Oncologyprofile →
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
2000606 citationsBeat Thürlimann, L. Mauriac et al.Journal of Clinical Oncologyprofile →
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
2001530 citationsAntonio Llombart‐Cussac, L. Mauriac et al.Annals of Oncologyprofile →
Author Peers
Peers are selected by citation overlap in the author's most active subfields.
citations ·
hero ref
This map shows the geographic impact of L. Mauriac's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Mauriac with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Mauriac more than expected).
This network shows the impact of papers produced by L. Mauriac. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Mauriac. The network helps show where L. Mauriac may publish in the future.
Co-authorship network of co-authors of L. Mauriac
This figure shows the co-authorship network connecting the top 25 collaborators of L. Mauriac.
A scholar is included among the top collaborators of L. Mauriac based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with L. Mauriac. L. Mauriac is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Tubiana-Hulin, M., Véronique Becette, Ivan Bièche, et al.. (2007). Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.. PubMed. 27(4C). 2689–96.17 indexed citations
8.
Belkacémi, Yazid, Joseph Gligorov, L. Mauriac, & D. Azria. (2006). [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].. PubMed. 93(10). 991–9.3 indexed citations
9.
Marty, Michel, Francesco Cognetti, D Maraninchi, et al.. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.. IRIS UNIMORE (University of Modena and Reggio Emilia).1162 indexed citations breakdown →
10.
Ellis, Matthew J., Andrew Coop, Baljit Singh, et al.. (2003). Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.. PubMed. 63(19). 6523–31.167 indexed citations
Mauriac, L., et al.. (2002). Standards, Options et Recommandations : cancers du sein infiltrants non métastatiques - 2e édition, mise à jour, version abrégée. Bulletin du Cancer. 89(2).5 indexed citations
Mauriac, L., Corinne Veyret, J. Wildiers, et al.. (1998). Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881. Ghent University Academic Bibliography (Ghent University).8 indexed citations
Mauriac, L., et al.. (1986). Votre unité Hers Girou certifié Qualité ISO 9001. Bulletin du Cancer. 73(2). 148–54.2 indexed citations
20.
Bioulac, Bernard, et al.. (1985). Thyroïdite d'Hashimoto et encéphalopathie myoclonique. Hypothèses pathogéniques.. Revue Neurologique. 141(1).7 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.